Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-27T18:31:09.860Z Has data issue: false hasContentIssue false

Melatonin deficiency at tissue level: a possible aetiological factor in nasal polyposis

Published online by Cambridge University Press:  24 June 2019

E Senturk*
Affiliation:
Department of Otorhinolaryngology, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey
Y S Yildirim
Affiliation:
Department of Otorhinolaryngology, Dogus University, Istanbul, Turkey
O Ozturan
Affiliation:
Department of Otorhinolaryngology, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey
S E K Tekkeli
Affiliation:
Department of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey
M V Kiziltaş
Affiliation:
Department of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey
*
Author for correspondence: Dr Erol Senturk, Department of Otorhinolaryngology, Bezmialem Vakif University, Adnan Menderes Boulevard, Istanbul 34600, Turkey E-mail: [email protected]

Abstract

Objective

The aim of this study was to examine whether melatonin is involved in the pathogenesis of nasal polyposis.

Method

This study included 29 patients with nasal polyposis and undergoing functional endoscopic sinus surgery. As a control group, 26 patients who had been operated on for a deviated nasal septum and concha bullosa were enrolled. Samples were taken from the nasal polyp tissue and from the resected middle concha bullosa mucosa of the control group. Serum samples were taken from all patients.

Results

It was found that the tissue and serum melatonin levels in the nasal polyp group were significantly lower compared with the tissue and serum melatonin levels in the control group.

Conclusion

In nasal polyposis, the melatonin level in the serum and tissue is lower than in individuals without polyposis. This deficiency may play a role in the pathogenesis of nasal polyposis.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited, 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr E Senturk takes responsibility for the integrity of the content of the paper

References

1Norlander, T, Brönnegård, M, Stierna, P. The relationship of nasal polyps, infection, and inflammation. Am J Rhinol 1999;13:349–5510.2500/105065899781367537Google Scholar
2Pawankar, R. Nasal polyposis: an update: editorial review. Curr Opin Allergy Clin Immunol 2003;3:1610.1097/00130832-200302000-00001Google Scholar
3Reiter, RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151–8010.1210/edrv-12-2-151Google Scholar
4Reiter, RJ, Maestroni, GJ. Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. J Mol Med (Berl) 1999;77:36–910.1007/s001090050297Google Scholar
5Cardinali, DP, Freire, F. Melatonin effects on brain: interaction with microtubule protein, inhibition of fast axoplasmic flow and induction of crystaloid and tubular formations in the hypothalamus. Mol Cell Endocrinol 1975;2:317–3010.1016/0303-7207(75)90019-2Google Scholar
6Ravindra, T, Lakshmi, NK, Ahuja, YR. Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci 2006;60:523–3510.4103/0019-5359.28983Google Scholar
7Jung, B, Ahmad, N. Melatonin in cancer management: progress and promise. Cancer Res 2006;66:9789–9310.1158/0008-5472.CAN-06-1776Google Scholar
8Maestroni, GJ, Conti, A. The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. J Neuroimmunol 1990;28:167–7610.1016/0165-5728(90)90031-HGoogle Scholar
9Calvo, JR, Rafii-el-Idrissi, M, Pozo, D, Guerrero, JM. Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. J Pineal Res 1995;18:119–2610.1111/j.1600-079X.1995.tb00149.xGoogle Scholar
10Gonzalez-Haba, MG, García-Mauriño, S, Calvo, JR, Goberna, R, Guerrero, JM. High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J 1995;9:1331–510.1096/fasebj.9.13.7557023Google Scholar
11García-Mauriño, S, Pozo, D, Carrillo-Vico, A, Calvo, JR, Guerrero, JM. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 1999;65:2143–5010.1016/S0024-3205(99)00479-8Google Scholar
12Yu, Q, Miller, SC, Osmond, DG. Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow. J Pineal Res 2000;29:869310.1034/j.1600-079X.2000.290204.xGoogle Scholar
13Silva, SO, Rodrigues, MR, Carvalho, SR, Catalani, LH, Campa, A, Ximenes, VF. Oxidation of melatonin and its catabolites, N 1-acetyl-N 2-formyl-5-methoxykynuramine and N 1-acetyl-5-methoxykynuramine, by activated leukocytes. J Pineal Res 2004;37:171–510.1111/j.1600-079X.2004.00149.xGoogle Scholar
14Kos-Kudla, B, Ostrowska, Z, Marek, B, Ciesielska-Kopacz, N, Kajdaniuk, D, Kudla, M et al. Diurnal rhythm of serum melatonin, ACTH and cortisol in asthma patients with long term glucocorticoid treatment. Endocr Regul 1997;31:4754Google Scholar
15Fei, GH, Liu, RY, Zhang, ZH, Zhou, JN. Alterations in circadian rhythms of melatonin and cortisol in patients with bronchial asthma. Acta Pharmacol Sin 2004;25:651–6Google Scholar
16Barriga, C, Martin, MI, Tabla, R, Ortega, E, Rodríguez, AB. Circadian rhythm of melatonin, corticosterone and phagocytosis: effect of stress. J Pineal Res 2001;30:180–710.1034/j.1600-079X.2001.300307.xGoogle Scholar
17Fidan, V, Alp, HH, Kalkandelen, S, Cingi, C. Melatonin and cortisol rhythm in patients with extensive nasal polyposis. Am J Otolaryngol 2013;34:61–410.1016/j.amjoto.2012.09.001Google Scholar
18Evsiukova, EV, Okuneva, Elu, Zubzhitskaia, LB, Kvetnoĭ, IM. Melatonin expression in nasal polyps in patients with asthmatic triad [in Russian]. Arkh Patol 2008;70:33–5Google Scholar